This dual activation of CD4+ and CD8+ T-cells in response to HER2-derived peptides underscores AE37’s potential as a therapeutic vaccine candidate, particularly for HER2-positive cancers, including breast cancer [297]. The gene discussed is CD8A; the disease is breast carcinoma.